A randomized, open label, multicentric, phase II clinical trial to assess the immunogenicity and safety of Measles, Mumps and Rubella (MMR) vaccine (Live) (Freeze-dried) of M/s Cadila Healthcare Ltd. in healthy pediatric subjects aged 15-18 months
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Measles mumps and rubella virus vaccine (Primary)
- Indications Measles; Mumps; Rubella
- Focus Pharmacodynamics
- Sponsors Cadila Healthcare
- 11 Nov 2014 Status changed from recruiting to completed.
- 19 Feb 2014 New trial record